美國發炎性腸道疾病治療市場規模、佔有率、趨勢分析報告：按類型、藥物類別、給藥途徑、分銷管道、地區、細分市場預測，2024-2030 年

美國發炎性腸道疾病疾病治療市場的成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，美國發炎性腸道疾病治療市場規模預計將達到141億美元，2024年至2030年複合年成長率為2.5%。

預計美國各地潰瘍性大腸炎和克隆氏症率的上升將推動預測期內的市場成長。發炎性腸道疾病（IBD）的發展被認為受到遺傳傾向、免疫系統功能障礙、環境因素、腸道微生物群失衡和生活方式因素的綜合影響。根據 2023 年發表的一篇論文，發炎性腸道疾病是一種相對常見的慢性疾病，影響超過 0.7% 的美國人，並且在東北部地區最受歡迎。越來越多的患者需要先進的治療方案，以推動市場成長。

克隆氏症和結腸炎基金會致力於加強產品開發，以改善發炎性腸道疾病患者的生活品質。該基金會正在推出專用的資助系統 Venture，以支持以產品為導向的研究和開發。

2023年9月，武田宣布FDA已接受生技藥品用於治療克隆氏症的ENTYVIO（通用名：vedolizumab）皮下給藥的生物製劑核准申請（BLA）。監管部門的核准為新藥、生技藥品和醫療設備進入市場鋪平了道路。這可以擴大 IBD 患者的治療選擇並改善治療結果和生活品質。

美國發炎性腸道疾病治療市場報告亮點

• 按類型分類，克隆氏症細分市場在 2023 年佔據最大銷售佔有率，佔據市場主導地位。如此大的比例是由於克隆氏症的慢性發炎性質造成的，它會影響胃腸道並引起腹痛、腹瀉、體重減輕和疲勞等症狀，需要更多的治療選擇和進步。
• 另一方面，由於潰瘍性大腸炎的盛行率不斷增加，預計在預測期內複合年成長率最快。
• 按藥物類別分類，TNF 抑制劑因其在控制症狀和抑制發炎方面的有效性而在 2023 年佔據最大的市場收入佔有率。
• 以給藥途徑分類，注射劑在 2023 年佔據最大的市場佔有率。注射藥物，例如生技藥品和生物學名藥，旨在針對參與發炎性腸道疾病發炎過程的特定蛋白質和細胞。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國發炎性腸道疾病治療市場變數、趨勢與範圍

• 市場體系展望
  • 母市場展望
  • 相關/附隨市場展望
• 市場動態
  • 市場推動要素分析
  • 市場限制因素分析
• 美國發炎性腸道疾病治療市場分析工具
  • 產業分析-波特五力分析
  • PESTEL分析

第4章美國發炎性腸道疾病治療市場：類型估計和趨勢分析

• 2023 年和 2030 年按類型分類的市場佔有率
• 細分儀表板
• 美國發炎性腸道疾病治療市場前景（按類型）
• 2018-2030年市場規模、預測及趨勢分析

第5章美國發炎性腸道疾病治療市場：藥物類別估計與趨勢分析

• 2023 年及 2030 年藥品類別市場佔有率
• 細分儀表板
• 美國發炎性腸道疾病治療市場前景（依藥物類別）
• 2018-2030年市場規模、預測及趨勢分析
• 胺基
• 皮質類固醇
• 腫瘤壞死因子抑制劑
• IL抑制劑
• 抗整合素
• JAK抑制劑

第6章美國發炎性腸道疾病治療市場：給藥途徑預估及趨勢分析

• 2023 年及 2030 年給藥途徑市場佔有率
• 細分儀表板
• 美國發炎性腸道疾病疾病治療市場：按途徑的前景
• 2018-2030年市場規模、預測及趨勢分析
• 口服
• 注射

第7章美國發炎性腸道疾病治療市場：通路估算及趨勢分析

• 2023 年及 2030 年分銷通路市場佔有率
• 細分儀表板
• 美國發炎性腸道疾病疾病治療市場：按分銷管道分類的展望
• 2018-2030年市場規模、預測及趨勢分析
• 醫院藥房
• 零售藥房
• 網路藥房

第8章美國發炎性腸道疾病治療市場：區域估計和趨勢分析

• 2023 年和 2030 年按地區分類的市場佔有率佔有率
• 美國發炎性腸道疾病治療市場：區域展望
• 2018-2030年市場規模、預測及趨勢分析
• 西
• 中西部
• 東北
• 西南
• 東南

第9章 競爭格局

• 主要市場參與企業的最新趨勢和影響分析
• 公司/競爭對手分類
• 供應商情況
• 公司簡介
  • Biogen
  • Novartis AG
  • Eli Lilly &Company
  • UCB SA
  • Celltrion Inc.
  • Merck &Co., Inc.
  • Johnson &Johnson Services, Inc.

U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends:

The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn's disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.

The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.

In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn's disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.

U.S. Inflammatory Bowel Disease Treatment Market Report Highlights:

• Based on type, the Crohn's disease segment dominated the market in 2023 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn's disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
• On the other hand, the ulcerative colitis segment is expected to register the fastest CAGR during the forecast period, owing to its increasing incidence rate.
• Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2023 due to their effectiveness in managing the symptoms and reducing inflammation.
• Based on route of administration, the injectable segment held the largest market share in 2023. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type
  • 2.2.2. Drug Class
  • 2.2.3. Route of Administration
  • 2.2.4. Distribution Channel
• 2.3. Competitive Insights

Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Inflammatory Bowel Disease Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Inflammatory Bowel Disease Treatment Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Inflammatory Bowel Disease Treatment Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 4.4.1. Crohn's Disease
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Ulcerative Colitis
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Inflammatory Bowel Disease Treatment Market: Drug Class Estimates & Trend Analysis

• 5.1. Drug Class Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. U.S. Inflammatory Bowel Disease Treatment Market by Drug Class Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 5.4.1. Aminosalicylates
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Corticosteroids
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.3. TNF Inhibitors
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. IL Inhibitors
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.5. Anti-integrin
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.6. JAK Inhibitors
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.7. Others
    • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Inflammatory Bowel Disease Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. U.S. Inflammatory Bowel Disease Treatment Market by Route of Administration Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 6.4.1. Oral
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Injectable
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. U.S. Inflammatory Bowel Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. U.S. Inflammatory Bowel Disease Treatment Market by Distribution Channel Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 7.4.1. Hospital Pharmacy
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.2. Retail Pharmacy
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.3. Online Pharmacy
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. U.S. Inflammatory Bowel Disease Treatment Market: Region Estimates & Trend Analysis

• 8.1. Regional Market Share, 2023 & 2030
• 8.2. U.S. Inflammatory Bowel Disease Treatment Market by Region Outlook
• 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 8.3.1. West
    • 8.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 8.3.2. Midwest
    • 8.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Northeast
    • 8.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.4. Southwest
    • 8.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.5. Southeast
    • 8.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company heat map analysis, 2023
• 9.4. Company Profiles
  • 9.4.1. Biogen
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Novartis AG
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Eli Lilly & Company
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. UCB S.A.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Celltrion Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Merck & Co., Inc.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Johnson & Johnson Services, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. inflammatory bowel disease treatment market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. inflammatory bowel disease treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 4 U.S. inflammatory bowel disease treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 5 U.S. inflammatory bowel disease treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 U.S. inflammatory bowel disease treatment market, by region, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. inflammatory bowel disease treatment market: market outlook
• Fig. 9 U.S. Inflammatory bowel disease treatment competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 U.S. inflammatory bowel disease treatment market driver impact
• Fig. 14 U.S. inflammatory bowel disease treatment market restraint impact
• Fig. 15 U.S. inflammatory bowel disease treatment market: Type movement analysis
• Fig. 16 U.S. inflammatory bowel disease treatment market: Type outlook and key takeaways
• Fig. 17 Crohn's Disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Ulcerative Colitis estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 U.S. inflammatory bowel disease treatment market: Drug class movement analysis
• Fig. 20 U.S. inflammatory bowel disease treatment market: Drug class outlook and key takeaways
• Fig. 21 Aminosalicylates market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 TNF inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 IL inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Anti-integrin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 JAK inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 U.S. inflammatory bowel disease treatment market: Route of administration movement analysis
• Fig. 28 U.S. inflammatory bowel disease treatment market: Route of administration outlook and key takeaways
• Fig. 29 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 U.S. inflammatory bowel disease treatment market: Distribution channel movement analysis
• Fig. 32 U.S. inflammatory bowel disease treatment market: Distribution channel outlook and key takeaways
• Fig. 33 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 U.S. inflammatory bowel disease treatment market: Regional movement analysis
• Fig. 37 U.S. inflammatory bowel disease treatment market: Regional outlook and key takeaways
• Fig. 38 West market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)